New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Requires DRESS Syndrome Warnings for Epilepsy Drugs

The agency warns that epilepsy drugs levetiracetam & clobazam are tied to life-threatening DRESS syndrome.

Moep
Moep

According to a recent LIVE SCIENCE article, the FDA has issued a warning about two widely prescribed epilepsy drugs, levetiracetam and clobazam. Apparently the drugs are linked to a rare but serious allergic reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Over 40 cases of DRESS syndrome have been reported worldwide in individuals taking these drugs, with the reaction being potentially life-threatening. 

The FDA advises those taking the drugs  to seek immediate medical attention if they experience unusual symptoms such as an unexplained rash, fever, or swollen lymph nodes. However, patients are cautioned against abruptly stopping the medications, as it could lead to uncontrolled seizures. The FDA is now requiring manufacturers to add warnings about DRESS syndrome to the drugs' prescribing information and patient medication guides to raise awareness of potential risks and early signs of the syndrome. 

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts